lecozotan SR (SRA-333)

Phase 3

PFIZER (PFE)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

10 competitors in Alzheimer Disease

SAVASimufilam

Phase 3

SNYxaliproden (SR57746A)

Drug Information

Target Indication

Alzheimer Disease

Clinical Trial

NCT00277810

Last updated: 12/17/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Insulin LisproPhase 3

Diabetes Mellitus

Cyclosporine APhase 3

Renal Transplantation

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts